Kornimate/medical-research-clean huggingface dataset:
environmental exposures and sudden unexpected infant death

Conditions: Sudden Unexpected Infant Death, Air Pollution, Pesticides

Summary: this project is a descriptive study designed to identify the exposure of infants who died of min to ambient air pollutants, and to measure pesticide concentrations in biological matrices (hair, serum, lcs) within a sample from the omin registry. french national registry of study of sudden unexpected infant death.

this project is a descriptive study designed to estimate the exposure of infants who died of min to ambient air pollutants, and to measure pesticide concentrations in biological matrices (hair, serum, lcs) within a sample from the omin registry. these two types of pollutants represent two important determinants of environmental health. although their emission sources and chemical composition differ, these pollutants carry the risk of multiple toxicities that can contribute to the occurrence of unexpected infant death syndrome (suid), and are widely present in france, in the air as well as in food, waterways, soils, etc. these two approaches have enabled us to develop two complementary methodologies: geostatistics associated with environmental epidemiology for air pollutants, and analytical environmental chemistry for pesticides. in addition to matching these exposure measurements with data from the omin registry, we will be able to address the impact and determinants of these exposures - i.e., to highlight the individual and collective characteristics that favor high exposure, and to address the toxicological mechanisms linked to these exposures and that may contribute to the occurrence of suid in general.

Eligibility criteria:
inclusion criteria: * died and include in french registry of sudden infant death syndrome exclusion criteria: * none

Keywords: sudden unexpected infant death sudden infant death syndrome perinatal death
endo-biliary laser excision of biliary stenoses

Conditions: Biliary Tract Disease; Bile Duct Obstruction

Summary: the biliary system normally empties into the intestines, however, some patients have biliary system narrow areas ("stenosis") that prevent the bile to drain normally. these may be related to an underlying disease or previous surgery. patients with this problem usually require tubes to be inserted into the biliary system to drain bile into a bag outside of their body, impacting their quality of life. the purpose of this research study is to use a laser device to try to re-open the biliary drainage system.

the current preferred minimally invasive treatment for surgically related or in-situ benign biliary stenosis (bbs) involves open surgical revision, endoscopic retrograde cholangiographic (ercp) or percutaneous transhepatic cholangiographic (ptc) balloon angioplasty and/or stent/biliary catheter placement. unfortunately, most patients are poor open surgical operative candidates. although ercp is the preferred secondary approach, anatomical restrictions often require ptc. additionally, previously placed biliary stents/catheters have poor long term patency and require routine exchange every 3-6 months. the vast majority of surgically related bbs patients are non-operative candidates for surgical revision of their bbs, and do not have favorable anatomy for ercp access. for patients who have failed aggressive ptc balloon angioplasty of their stenoses, treatment consists of indefinite biliary catheter exchanges every 3 months. lifelong biliary catheter dependence severely impacts the quality of life in an otherwise healthy patient with no additional evidence of their initial disease process. a potential long-term therapy to alleviate bbs that has not been explored is the use of laser excision of the fibrotic tissue responsible for these stenoses. therapeutic applications of lasers in medicine is not a novel concept. its use has been well documented in the urologic tract to ablate tissue (benign prostatic hypertrophy) and renal stones. recent laser therapeutic use in the biliary tract to dissolve gallstones has been described. the laser excision of bbs has potential to provide long term alleviation of bbs. the primary endpoint of this feasibility study is to assess the safety and initial efficacy of bbs laser excision.

Eligibility criteria:
inclusion criteria: * subjects with diagnosed benign biliary stenosis * initial total serum bilirubin \> 1.9 mg/dl * subjects currently having an internal/external percutaneous biliary drain * subjects that have failed at least 3 separate biliary stenosis balloon angioplasties and are deemed non-surgical candidates by the transplant and/or pancreaticobiliary surgical services at the university of florida

Keywords: benign biliary stenosis laser excision
performance of the salt lake mask system

Conditions: Obstructive Sleep Apnea

Summary: assessment of the performance of the salt lake mask system acting as a patient interface in the provision of pap therapy. this study will assess the suitability of this mask system in its current form for use.

sleep-disordered breathing (sdb) is a significant direct cause of morbidity and mortality, as well as being a significant indirect cause of morbidity and mortality impacting greatly upon health and quality of life when left untreated. positive airway pressure (pap) therapy is an effective and proven form of medical treatment for many types of sdb. in order for pap therapy to be effective, patient interfaces(masks) need to be both effective in their delivery of this treatment and accepted by prospective and current patients for use. this study will investigate the ability of the salt lake mask system to act effectively as a patient interface in pap therapy, and its ability to be accepted by patients.

Eligibility criteria:
inclusion criteria: * patients willing to give written informed consent * patients who can read and comprehend english * patients using the swift fx mask system * patients who can trial the mask for 7 nights * patients who have used pap therapy for a minimum of 6 months. exclusion criteria: * patients not willing to give written informed consent * patients who can not read and comprehend english * patients using an inappropriate mask system * patients using bilevel flow generators * patients who are pregnant * patients who are unable to comply with the protocol * patients who have used pap therapy for less than 6 months.
characteristics of pneumothorax associated with transthoracic percutaneous lung biopsy in standard of care

Conditions: Pneumothorax Iatrogenic Postprocedural

Summary: the number of lung biopsies has increased steadily in recent years. pneumothorax is the most common complication of a lung biopsy and can occur during the procedure, immediately after the procedure or within a few hours (delayed pneumothorax). the incidence of pneumothorax in the literature is very different from one study to another: it has been reported to be from 9 to 54% in patients undergoing percutaneous transthoracic needle biopsy. this difference of incidence could be explained by the absence of consensus for the definition of an iatrogenic pneumothorax. the characteristics of pneumothorax and the management of patients with iatrogenic pneumothorax will be evaluated in different centres in a retrospective manner. this study will contribute to refining the criteria for defining pneumothorax occurring during lung biopsy and will provide a better understanding of the condition and its management.


Eligibility criteria:
inclusion criteria: * patients aged 18 years old and more at the time of the biopsy procedure in year 2020 * having had a pneumothorax following their transthoracic percutaneous lung biopsy in year 2020 exclusion criteria: * objection to the use of the data (french sites only)

Keywords: interventional radiology, iatrogenic pneumothorax, transthoracic lung biopsy, pneumothorax rate, pneumothorax characteristics, patient management
effect of oral and intravenous diltiazem protocol for emergency department atrial fibrillation

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: the primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for af and atrial flutter in the emergency department of spectrum health lakeland. secondary outcome is to measure if oral diltiazem is an effective hr controlling agent in af rvr and flutter.


Eligibility criteria:
inclusion criteria: * heart rate \>125 * systolic bp\>110 * atrial fibrillation/flutter confirmed on ecg. * meets observation unit requirements (performs certain adl's (acts of daily living) * age\>18. exclusion criteria: * wolf-parkinson-white syndrome * st elevation myocardial infarction * pregnant * clinical diagnosis of sepsis, * decompensated hf * allergy to diltiazem * provider discretion * clinical need for cardioversion
yoga intervention for substance use and art adherence in community reentry

Conditions: Substance Related Disorders; HIV

Summary: people with hiv and a substance use disorder who are reentering the community from prison or jail face the dual risks of relapse and interruptions in adherence to antiretroviral therapy (art) medication. this mixed-methods randomized controlled trial will compare the stress, substance use and art adherence outcomes of participants in a 12-session, 90-minute weekly yoga group intervention with participants in a treatment as usual control group. all participants are re-entering the community, have hiv and experience substance use challenges.


Eligibility criteria:
inclusion criteria: * have hiv * experience substance use challenges, within one year of reentry from prison or jail
computer-based attention training in patients with acquired brain injury

Conditions: Brain Injuries

Summary: investigates computer based cognitive rehabilitation and training using the n-back task with a visual search task as an active control. the overall purpose is to provide (further) evidence about the efficacy (or lack of efficacy) of the n-back task and to find points of convergence and divergence between patients with acquired brain injury and non-impaired subjects.


Eligibility criteria:
inclusion criteria: * subjects should be able to do both task at level at the time of recruitment * informed consent * (for brain injured patients) training must not interfere with treatment as usual. * (for brain injured patients) no symptoms which hinder testing and training. i.e. aphasia, deafness, tetraplegia etc.

Keywords: cognitive training cognitive rehabilitation acquired brain injury n-back visual search cognitive transfer
real world outcomes study of hepatic encephalopathy patients' experience on rifaximin (prosper)

Conditions: Hepatic Encephalopathy

Summary: this study evaluates hepatic encephalopathy (he) and liver-related hospitalization rates and duration of stay in patients with he treated with rifaximin-α 550mg compared to patients receiving other therapies. this registry study aims to comprehensively and rigorously characterize the impact of rifaximin-α 550 mg on hospitalization, clinical safety and effectiveness outcomes, and quality of life in patients with he in europe and australasia.

whilst clinical trial data and a few small observational studies have demonstrated the potential of rifaximin-α 550 mg to reduce overt he episodes and hospitalizations, there is a need by physicians, commissioners and other healthcare professionals caring for patients with he to understand the impact of management with rifaximin-α 550 mg on healthcare resource use in real world clinical practice. currently available data are from evaluations undertaken in single uk centres. in addition, the overall burden of he has not been well characterized, including the impact on patient quality of life, or impaired productivity incurred by patients' caregivers. this multinational, multicentre disease registry study aims to comprehensively and rigorously characterize the impact of rifaximin-α 550 mg on hospitalization, clinical safety and effectiveness outcomes, and quality of life in patients with he in europe and australasia. the study will expand upon previous work in the following ways: * provide characterization of the burden of he and the impact of rifaximin-α 550 mg in a real world setting, to complement rct evidence; * allow for more rigorous characterization of the impact of rifaximin-α 550 mg on patient outcomes for individuals with he over time. this will be achieved by prospectively enrolling patients not taking rifaximin-α 550 mg to characterize outcomes over time in the absence of treatment, and by assessing the quality of life and workplace productivity implications of he. there will be no change to the management of patients for the purposes of this study beyond normal clinical practice.

Eligibility criteria:
inclusion criteria: * diagnosis of cirrhosis; * patient is ≥18 years of age; * patient is enrolled within 12 weeks of resolution of an episode of overt he associated with a hospital visit; * patient is able to provide informed consent to participate in the study (individually or via caregiver); * patient meets clinical eligibility to receive rifaximin-α 550 mg in the opinion of the participating physician, regardless of he treatment actually received. exclusion criteria: * west haven conn score of ≥2 at time of study entry (i.e. at provision of informed consent); * mental health disorder such as dementia or psychosis which makes diagnoses of he questionable; * prior treatment with rifaximin in the 12 months before qualifying episode of overt he associated with a hospital visit; * contraindications to the use of rifaximin-α as per local summary of product characteristics
effects of early stage mini-invasive abdominal drainage on complications and prognosis of sap

Conditions: Pancreatitis

Summary: this study aims to standardized the process of mini-invasive abdominal draniage of sap in early stage.to determine the indications and occasion.

pancreatitis associated ascetic fluids(paaf) gather with the beginning of sap and induced iap(intra-abdominal pressure) increasement.with an excess of 12mmhg ,iap presents as iah(intra-abdominal hypertension) and when a ≥20mmhg iap accompanied with at least one organ's dysfunction it is acs(abdominal compartment syndrome).previous recommended theraphy of acs is laparotomy.however,with inherited advantages such as ease-to-operate and minimal invassiveness, early stage mini-invasive abdominal drainage therapies , for example, percutaneous catheter drainage(pcd) instructed by ultrasound or ct ,have shown a promised future in recent years. it is reported that patients acquired pcd decreased 81% in operation rate compared to those who did not and had lower mortality rate. whereas, the operation flow of early stage mini-invasive abdominal drainage remains controversial, and whose validity calls for evidence from large-scale clinical trials.

Eligibility criteria:
inclusion criteria: 1.diagnosis of pancreatitis 2.onset of abdominal pain within 72h 3.moderate severe or severe ap according to atlanta criteria revisited in 2012 4.intravesical pressure≥20cmh2o 4.ct images:acute peripancreatic liquid collection - exclusion criteria: 1.pregnancy 2.heart function: nyha \>ii 3.pacemaker implantation 4.copd 5.ckd 6.pre-existing disease with life expectancy \ 25cmh2o 9.at least one organ's newly emerged dysfunction -

Keywords: pancreatitis early stage mini-invasive abdominal drainage
pilot study of duloxetine in adult attention deficit hyperactivity disorder(adhd)

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to determine whether duloxetine is an effective treatment of attention deficit disorder in adults.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of adhd of at least moderate intensity * able to give consent * able to swallow capsules exclusion criteria: * allergic or do not tolerate duloxetine * under psychotherapy for adhd * taking a medication that interacts with duloxetine, including all psychotropic medication * treated with medication for adhd * unstable medical condition * severe renal insufficiency * liver insufficiency * substance/alcool abuse or dependency in the last 6 months * pregnancy, nursing or inadequate contraceptive methods * suicide or homicide risk * organic brain syndrome * any diagnosis of lifetime bipolar disorder or psychotic disorder, and any actual diagnosis of anxious disorder or major depressive disorder

Keywords: attention deficit disorder with hyperactivity duloxetine adult addh adhd
hybrid peek-acrylic resin prostheses and the all-on-4 concept for full-arch rehabilitation - routine group

Conditions: Prosthesis Survival

Summary: the goal of this observational study is to evaluate the outcome of a poly-ether-ether-ketone - acrylic resin prosthesis for full-arch rehabilitation of the atrophic maxillae through the all-on-4 concept after five years of follow-up. the main question it aims to answer is: - what is the survival outcome of the full-arch implant-supported poly-ether-ether-ketone - acrylic resin prosthesis? the participants already rehabilitated with dental implants will receive a poly-ether-ehter-ketone prosthesis as a definitive prosthesis.

following the learning generated during a development study with implant supported fixed prostheses using polyetheretherketone (peek) material, it is necessary to evaluate the outcome of implant supported fixed prosthetic rehabilitations using peek material in a routine scenario, following optimized laboratory and treatment protocol. the study design will be a prospective single cohort to evaluate the long term outcome of fixed prosthetic implant supported rehabilitations. the cohort will be evaluated at 6 months, 12 months and annually thereafter until 5 years of follow-up. at each follow-up assessments multiple evaluaitons will be performed to assess the overall outcome of the restorations.

Eligibility criteria:
inclusion criteria: * patients rehabilitated with immediate function implants for complete edentulous arches through the all-on-4 concept. * patients in need of definitive implant-supported restorations. * written informed consent from each patient to participate in the study. exclusion criteria: - hindrance to provide written informed consent. (a patient cannot participate if no written consent is given)

Keywords: prosthesis peek all-on-4 all-on-four dental implants
cervical cancer in french guiana: screening between 2006-2011

Conditions: Cervical Cancer

Summary: given that cervical cancer is the second most frequent cancer among women in french guiana the aim of the study was to determine the screening rate among women living in french guiana. cervical smears are read in 2 laboratories which allowed us to compute screening rates per 100 women-years. overall the screening activity was 23.5-25.8 smears per 100 women-years. between 2006 and 2011 54% of women were screened. these baseline figures will allow to evaluate present efforts to increase the screening rate for this frequent cancer in french guiana.


Eligibility criteria:
inclusion criteria: * women screened exclusion criteria: -
trial evaluating transvaginal electrical stimulation with a home use programmable device for urinary stress incontinence

Conditions: Urinary Stress Incontinence

Summary: to compare the effectiveness of a transvaginal electrical stimulation by a home use programmable device to a placebo device for urinary incontinence in women


Eligibility criteria:
inclusion criteria: * \>=18 years old * signed informed consent form * women with urinary stress incontinence defined as follow * involuntary loss of urine during increased abdominal pressure. in case of mix urinary incontinence (i.e., stress urinary incontinence associated to urge urinary incontinence) the discomfort related to stress incontinence as evaluated on a 0 (no discomfort) to 100 (maximum discomfort) visual analogic scale is higher for stress incontinence than for urge incontinence symptoms. * closure pressure between 10 and 60 cm h2o * the discomfort related to stress incontinence as evaluated on a 0 (no discomfort) to 100 (maximum discomfort) visual analogical scale is higher than 40/100 * patients never treated with transvaginal electrical stimulation * vaginal muscle strength less than 3/5 on the muscular testing * positive pad test (\>2 g of leakage measure by pad test with standardised bladder volume) exclusion criteria: * patient refusing to sign the consent form * patient unable to understand or follow the protocol * inadequate cognitive ability * patient participating in another research protocol within the 3 previous months * pregnancy * women with no contraception * pacemaker * history of recent (\< 1 year) transvaginal electrical stimulation treatment at home * urinary incontinence other than stress incontinence * neurological disease * permanent metrorrhagia * ongoing urinary tract infections * vaginal prolapse \> 2 * untreated atrophic vaginitis * history of surgical treatment for urinary stress incontinence or genital prolapse * recent pelvic surgery (\<6 months) * anatomic defect that preclude the use of the device * genitourinary cancer or colic cancer * patient already treated for urinary stress incontinence * recent oestrogen treatment (less than 3 weeks)

Keywords: urinary stress incontinence urinary stress incontinence in women